Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab

Mepolizumab is an anti-interleukin-5 (IL-5) humanized monoclonal antibody that has been recently approved as an add-on biological treatment for severe eosinophilic asthma, by both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Moreover, mepolizumab is also current...

Descripción completa

Detalles Bibliográficos
Autores principales: Pelaia, Corrado, Vatrella, Alessandro, Busceti, Maria Teresa, Gallelli, Luca, Terracciano, Rosa, Savino, Rocco, Pelaia, Girolamo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5669784/
https://www.ncbi.nlm.nih.gov/pubmed/29133975
http://dx.doi.org/10.2147/DDDT.S150656

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5669784/
https://www.ncbi.nlm.nih.gov/pubmed/29133975
http://dx.doi.org/10.2147/DDDT.S150656

Ejemplares similares